National University of Ireland

Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer

Retrieved on: 
Monday, January 9, 2023
Agitation, Migraine, Central nervous system, Food, MDD, Therapy, Bipolar disorder, CORAL, Institute of Psychiatry, Psychology and Neuroscience, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Business, Pfizer, National University of Ireland, Alzheimer's disease, New York University Grossman School of Medicine, MBA, Narcolepsy, CNS, National university, Medical Affairs Bureau, New York University Stern School of Business, Schizophrenia, Cognition, Psychiatry, Senior, Pharmaceutical industry, Medical device

CORAL GABLES, Fla., Jan. 9, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of Cedric O'Gorman MD as the Company's Chief Medical Officer.

Key Points: 
  • CORAL GABLES, Fla., Jan. 9, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of Cedric O'Gorman MD as the Company's Chief Medical Officer.
  • Dr. O'Gorman brings to Relmada more than two decades of life sciences experience in clinical development, medical affairs and medical strategy, with significant expertise in the CNS therapeutics field.
  • Most recently, he served as Chief Medical Officer at Alpha Cognition, where he led clinical development programs for the company's Alzheimer's disease targets.
  • "Dr. O'Gorman adds important depth to our management team given his extensive CNS medical and research experience, and his demonstrated leadership acumen," stated Sergio Traversa, Relmada's Chief Executive Officer.

Sartorius names Maurice Phelan as new President for North America

Retrieved on: 
Tuesday, January 3, 2023
ID Labs production discography, Membrane, Merck Millipore, Sartorius, FBI Criminal Justice Information Services Division, BioAnalyt, Physics, National University of Ireland, Laboratory, Quality control, National university, GE Healthcare, Head, Vaccine, Research, Chemistry, Fine chemical

BOHEMIA, N.Y., Jan. 3, 2023 /PRNewswire/ -- Sartorius, a leading international partner of life science research and the biopharmaceutical industry, announces Maurice Phelan has assumed the role of President of Sartorius North America.

Key Points: 
  • BOHEMIA, N.Y., Jan. 3, 2023 /PRNewswire/ -- Sartorius, a leading international partner of life science research and the biopharmaceutical industry, announces Maurice Phelan has assumed the role of President of Sartorius North America.
  • Sartorius North America, headquartered in Bohemia, New York, currently employs more than 3,000 employees across 17 sites in the United States and Canada.
  • Mr. Phelan has spent many years in the industry and recently rejoined Sartorius from Repligen, where he was Vice President of Fluid Management.
  • Against a backdrop of fundamentally strong market dynamics, Sartorius has been investing considerably in building new capacities in North America.

Freezing of Gait Treatment Market Report 2022: Increasing Chronic Parkinson's Disease Along With Significant Admissions in the Hospitals Internationally Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, August 19, 2022
Health, Other Health, FDA, Carbidopa, FGT, Deep brain stimulation, Parkinson's disease, OFF, The Michael J. Fox Foundation, Korea, Teva Pharmaceuticals, Acorda Therapeutics, L-DOPA, Industry, Population, Technology, Growth, Freezing, NUI Galway, Prevalence, Hospital, National university, Chapter Five, Chapter Three, Smartglasses, Health, Patient, National University of Ireland, Therapy, Conditional sentence, Awareness, CES, CAGR, Geography, Gait, Chapter Six, Robotics, Fog, US, Walking, Kyungpook National University, Android, Organization, Pharmaceutical industry, PD

The global freezing of gait treatment market is growing effectually, expected to grow at a CAGR of 7.2%.

Key Points: 
  • The global freezing of gait treatment market is growing effectually, expected to grow at a CAGR of 7.2%.
  • FDA approval for new drugs, and promising pipeline products in the equipment and devices segment in the Parkinson's disease industry are driving the overall growth freezing of gait treatment market globally.
  • Levodopa (InbrijaT, by Acorda Therapeutics), along with carbidopa, remains the optimum standard of symptomatic treatment for (FoG) Parkinson disease orally.
  • Increasing chronic Parkinson's disease (PD) along with significant admissions in the hospitals internationally are notable factors expected for the growth of the market.

Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain

Retrieved on: 
Monday, June 27, 2022
FDA, Patient, Anxiety, Cannabinoid, Protein, National University of Ireland, Securities Act of 1933, Research, Securities Exchange Act of 1934, ICRS, Peripheral neuropathy, GLOBE, International Cannabinoid Research Society, Â, Cancer, Company, Industry, U.S. Securities and Exchange Commission, Lipid, Pain, FABP, Organic acid, Inflammation, Oxaliplatin, Therapy, Purging disorder, Drug Quality and Security Act, Cannabis, Clinical and Translational Science, Nasdaq, Private Securities Litigation Reform Act, Analgesic, Twitter, FABP5, Nature, Interest, National university, Security (finance), Pharmaceutical industry, CIPN

These results support further development of ART26.12 in neuropathy associated with chemotherapy and other neuropathies, continued Professor OSullivan.

Key Points: 
  • These results support further development of ART26.12 in neuropathy associated with chemotherapy and other neuropathies, continued Professor OSullivan.
  • Development of therapeutics for CIPN represents an attractive, new opportunity for Artelos FABP5 inhibitors, said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences.
  • Various inhibitors of FABPs may be particularly useful for the treatment of specific cancers, neuropathic and nociceptive pain, and anxiety disorders.
  • Artelo Biosciences, Inc.is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system.

Kyowa Hakko USA Announces the Appointment of Dr. Colin Hill to the Scientific Advisory Board of Award-Winning Postbiotic IMMUSE™

Retrieved on: 
Thursday, May 19, 2022
University College Cork, Probiotic, MBA, Education, Knowledge, National university, American Academy, NEW, Royal Irish Academy, Leadership, Science, International Scientific Association for Probiotics and Prebiotics, SFI, APC, Health, Postbiotic, School, Marketing, Prebiotic (nutrition), Feedback, Interview, Research, Kyōwa, NK, Principal, ISI, Decision-making, Bacteriocin, RD, National University of Ireland, Immune system, Kyowa Hakko Kirin, PDC, Publication, Google, Medical device, Fine chemical, Vaccine, Microbiology

NEW YORK, May 19, 2022 /PRNewswire-PRWeb/ -- Kyowa Hakko adds distinguished professor Dr. Colin Hill to the IMMUSE™ Scientific Advisory Board to further advance the understanding and education of postbiotics and the definition of postbiotics by ISAPP (International Scientific Association for Probiotics and Prebiotics). Dr. Hill's role will include participating in group discussions as a postbiotic expert and providing scientific group evaluation and feedback.

Key Points: 
  • NEW YORK, May 19, 2022 /PRNewswire-PRWeb/ -- Kyowa Hakko adds distinguished professor Dr. Colin Hill to the IMMUSE Scientific Advisory Board to further advance the understanding and education of postbiotics and the definition of postbiotics by ISAPP (International Scientific Association for Probiotics and Prebiotics).
  • Dr. Hill's role will include participating in group discussions as a postbiotic expert and providing scientific group evaluation and feedback.
  • Dr. Hill will help lead Kyowa Hakko's future efforts in postbiotics".
  • Media interested in setting up an interview with Dr. Hill or Karen Todd, please contact Giselle Chollett: [email protected] or 917.386.7116.

Satellogic Elects Tom Killalea to its Board of Directors

Retrieved on: 
Wednesday, March 30, 2022
Satellite, Photography, Data Management, Audio, Video, Technology, Carbon, Company, Risk, Amazon, COF, Organization, Economics, NASDAQ, Form, Chief of staff, Leadership, Forward-looking statement, Caterpillar, Climate change, Orbit, Board, NYSE, Capital One, Security, EO, Trinity College Dublin, Probability, Sustainability Accounting Standards Board, PayPal, CEO, U.S. Securities and Exchange Commission, Board of directors, Senior, Entrepreneurship, National university, Prospectus, Computer science, Security (finance), Association, Technology, Industry, VMware, General Joseph Colton, SEC filing, MercadoLibre, National University of Ireland, Solution, Carbon black, Treasury, Founder, MongoDB, AKAM, Joint Chiefs of Staff, Education, Trinity College, Food security, Distributed computing, Collection, Management, Risk management, Satellogic, Xoom, Akamai Technologies, Killalea

Satellogic Inc. (NASDAQ: SATL), a leader in sub-meter resolution satellite imagery collection, announced it has elected Tom Killalea to its Board of Directors (the Board).

Key Points: 
  • Satellogic Inc. (NASDAQ: SATL), a leader in sub-meter resolution satellite imagery collection, announced it has elected Tom Killalea to its Board of Directors (the Board).
  • Mr. Killaleas election as an independent director increases the total number of Board members to eight, with five independent directors.
  • Killalea is Chairman of the board of MongoDB (NASDAQ: MDB) and serves on the board of Capital One (NYSE: COF) and of Akamai (NASDAQ: AKAM).
  • We are thrilled to welcome Tom to our Board of Directors, stated Emiliano Kargieman, CEO of Satellogic.

WhiteSwell Adds Experienced Executives to its Senior Management Team

Retrieved on: 
Wednesday, January 26, 2022
Technology, Research, Medical Devices, Clinical Trials, Cardiology, Software, Hardware, Health, Science, Linda, University, Mechanical, Leadership, Canadian International Council, International Journal of Cardiology, Institute, Patient, Congestion, Mechanical engineering, Swelling, Nursing, Heart, VP, Engineer, HF, Clinical, Boston Scientific, National University of Ireland, Edema, Homeostasis, Integration, University of St. Thomas (Minnesota), National university, Diagnosis, Martin, Acute decompensated heart failure, Lymphatic system, Clinical trial, CEO, Tissue, Master of Engineering, Integrated assessment modelling, MBA, Hospital, Institution, Heart failure, Fatigue, Electronics, IDE, Pharmaceutical industry, Cardiology, ADHF, Medtronic, Science, the Lymphatic System and ADHF, WhiteSwell, THE LYMPHATIC SYSTEM AND ADHF, WHITESWELL

Linda joins WhiteSwell from Medtronic, where she directed numerous clinical research teams.

Key Points: 
  • Linda joins WhiteSwell from Medtronic, where she directed numerous clinical research teams.
  • She previously served as Vice President of Clinical Affairs at Respicardia, where she led successful execution of a randomized, pivotal IDE clinical trial.
  • Both Linda and Martin bring extensive experience and seasoned leadership to the WhiteSwell team, said Eamon Brady, CEO.
  • With a powerful senior management team in place, WhiteSwell is well positioned to advance its pioneering treatment of acute decompensated heart failure by leveraging the lymphatic system.

Chubb Names Miriam Connole Chief Financial Officer for its International General Insurance Operations; John Jones to Retire

Retrieved on: 
Tuesday, January 25, 2022
Bachelor of Commerce, Commerce, NYSE, Burford Capital, CIGNA, New, Parent, Industry, Combined Insurance, AIG, Insurance, National University of Ireland, Multimedia, P&C, National university, Chartered accountant, Chubb Limited, Comptroller, Friends Life Group, RSA, Technology, ACE, Financial management, CFO, University College Dublin, Foundation, Management, Chubb

NEW YORK, Jan. 25, 2022 /PRNewswire/ -- Chubb today announced that Miriam Connole has been appointed Chief Financial Officer for Overseas General Insurance, the company's international general insurance operations.

Key Points: 
  • NEW YORK, Jan. 25, 2022 /PRNewswire/ -- Chubb today announced that Miriam Connole has been appointed Chief Financial Officer for Overseas General Insurance, the company's international general insurance operations.
  • Ms. Connole will succeed John Jones, who is retiring from Chubb in March after 43 years with the company.
  • Ms. Connole will report to Juan Luis Ortega, Executive Vice President, Chubb Group and President, Overseas General Insurance and to Peter Enns, Executive Vice President, Chubb Group and Chief Financial Officer.
  • "Miriam has been an exceptional leader in our organization for many years, in different roles and geographies," said Mr. Ortega.

FANACCI reveals its Clothing Line [1] - 'The Most Advanced and Versatile Clothing Collection' on Kickstarter

Retrieved on: 
Tuesday, January 18, 2022
List, National Medal of Technology and Innovation, 6126 (clothing line), Collection, CEO, National university, Clothing, Technology transfer, Blazer, Industry, Ecosystem, University College Dublin, NUIG, Kickstarter, Technology, Entrepreneurship, National University of Ireland, Trousers, Marketing, Fashion, Tailor, Management

LONDON, Jan. 18, 2022 /PRNewswire/ -- FANACCI 's fashion-tech Clothing Line [1]- the most advanced and versatile clothing collection, has been officially revealed and launched for pre-orders today on Kickstarter.

Key Points: 
  • LONDON, Jan. 18, 2022 /PRNewswire/ -- FANACCI 's fashion-tech Clothing Line [1]- the most advanced and versatile clothing collection, has been officially revealed and launched for pre-orders today on Kickstarter.
  • FANACCI is a London-based lifestyle technology start-up.The company's mission is to improve the performance and lifestyle of modern dynamic individuals, by making thoughtfully engineered wearable products.
  • The 5 products are worth 1085 ($1465) and during the Kickstarter campaign the entire collection can be pre-ordered starting at 488 ($659).
  • FANACCI was co-founded by CEO Dr. Farhaan Essoof, a medical doctor, health-tech researcher, and technology & innovation specialist with 10+ years of experience in the clothing industry.

PCOM Appoints Dr. Ruth Maher as PT Department Chair

Retrieved on: 
Thursday, October 7, 2021
UCD, Therapy, Jammu and Kashmir State Board of School Education, PCOM, Physical therapy, Federation, Doctor of Philosophy, The Science, Engineering & Technology Student of the Year Awards, Interprofessional education, International Continence Society, Department, American Institute, Osteopathy, University college, American Institute of Ultrasound in Medicine, Academy, Multimedia, National University of Ireland, PT, Education, American Physical Therapy Association, University College Dublin, FDA, Health, American Board of Physical Therapy Specialties, Simmons University, National university, Philadelphia College of Osteopathic Medicine, American Board of Commissioners for Foreign Missions, Pharmacy, DPT, Osteopathic medicine in the United States, Urinary incontinence, Association, Georgia State University, Gold, Physical, Medicine

SUWANEE, Ga., Oct. 7, 2021 /PRNewswire/ --Philadelphia College of Osteopathic Medicine has named Professor Ruth M. Maher, PT, PhD, DPT, a board-certified clinical specialist in women's health from the American Board of Physical Therapy Specialties, as the chair of the Department of Physical Therapy.

Key Points: 
  • SUWANEE, Ga., Oct. 7, 2021 /PRNewswire/ --Philadelphia College of Osteopathic Medicine has named Professor Ruth M. Maher, PT, PhD, DPT, a board-certified clinical specialist in women's health from the American Board of Physical Therapy Specialties, as the chair of the Department of Physical Therapy.
  • Dr. Maher has held positions with the American Board of Physical Therapy Specialties, women's health council and several committees within the Federation of State Boards of Physical Therapy.
  • Established in 2005, PCOM Georgia is a private, not-for-profit, accredited institute of higher education dedicated to the healthcare professions.
  • PCOM Georgia offers doctoral degrees in osteopathic medicine, pharmacy, and physical therapy and graduate degrees in biomedical sciences and physician assistant studies.